PDF(Pubmed)
Abstract：
UNASSIGNED: The vaccines developed against COVID-19 have different modes of action, with a primary focus on the spike protein of the virus. Adverse effects following vaccination have been reported, including local and systemic symptoms. Understanding the potential side effects on the urinary tract after vaccination is of importance. Actively investigating and comprehending the potential impact on the urinary tract, we can enhance public health strategies and pave the way for safer and more effective vaccination programs.
UNASSIGNED: The study was based on an online survey that included the Spanish Version of the Overactive Bladder Symptom Score (OABSS-S); 2,362 men and women replied to the survey. After the application of the exclusion criteria, 1,563 participants were insured. In the context of COVID-19, individuals were questioned regarding several key factors related to their vaccination status and medical history. These factors included the number of vaccine doses received, the specific type of vaccine administered, whether they had previously contracted COVID-19, and the frequency of prior infections, if applicable.
UNASSIGNED: A total of 1,563 (74.7% women and 27.3% men) subjects between the ages of 18 and 45 completed the survey and were included in the final analyses. The most frequently administered vaccine type was Pfizer-BioNTech (42.2%), and most subjects received three doses. The proportion of females who received the AstraZeneca vaccine and do not require to urinate during the night is significantly higher compared to males (59.1% vs. 33.3%; p<0.05). The proportion of individuals who urinate five or more times during the night is higher in those who have received a single vaccine dose than in those who have received three doses (2.2% vs. 0.1%; p<0.05).
UNASSIGNED: COVID-19 vaccination has been found to impact the lower urinary tract (LUT) and overactive bladder (OAB). Initially, LUT symptoms worsened, and OABSS-S scores increased after the first vaccine dose in individuals under 45 years old. However, symptoms improved after receiving the third and fourth doses. Gender differences were observed in the vaccination effects. Men vaccinated with AstraZeneca reported a higher number of nighttime voids, while women vaccinated with Moderna reported more daytime voids.
UNASSIGNED: The study was based on an online survey that included the Spanish Version of the Overactive Bladder Symptom Score (OABSS-S); 2,362 men and women replied to the survey. After the application of the exclusion criteria, 1,563 participants were insured. In the context of COVID-19, individuals were questioned regarding several key factors related to their vaccination status and medical history. These factors included the number of vaccine doses received, the specific type of vaccine administered, whether they had previously contracted COVID-19, and the frequency of prior infections, if applicable.
UNASSIGNED: A total of 1,563 (74.7% women and 27.3% men) subjects between the ages of 18 and 45 completed the survey and were included in the final analyses. The most frequently administered vaccine type was Pfizer-BioNTech (42.2%), and most subjects received three doses. The proportion of females who received the AstraZeneca vaccine and do not require to urinate during the night is significantly higher compared to males (59.1% vs. 33.3%; p<0.05). The proportion of individuals who urinate five or more times during the night is higher in those who have received a single vaccine dose than in those who have received three doses (2.2% vs. 0.1%; p<0.05).
UNASSIGNED: COVID-19 vaccination has been found to impact the lower urinary tract (LUT) and overactive bladder (OAB). Initially, LUT symptoms worsened, and OABSS-S scores increased after the first vaccine dose in individuals under 45 years old. However, symptoms improved after receiving the third and fourth doses. Gender differences were observed in the vaccination effects. Men vaccinated with AstraZeneca reported a higher number of nighttime voids, while women vaccinated with Moderna reported more daytime voids.
摘要：
■针对COVID-19开发的疫苗具有不同的作用方式，主要关注病毒的刺突蛋白。已报道疫苗接种后的不良反应，包括局部和全身症状。了解疫苗接种后对泌尿道的潜在副作用非常重要。积极调查和理解对泌尿道的潜在影响，我们可以加强公共卫生战略，为更安全、更有效的疫苗接种计划铺平道路。
该研究基于一项在线调查，其中包括西班牙语版膀胱过度活动症症状评分（OABSS-S）；2,362名男性和女性回答了该调查。应用排除标准后，1,563名参与者参加了保险。在COVID-19的背景下，个体被问及与其疫苗接种状况和病史相关的几个关键因素。这些因素包括接受的疫苗剂量，所施用的特定类型的疫苗，他们以前是否感染过COVID-19，以及以前感染的频率，如果适用。
■共有1,563名18至45岁的受试者（74.7％的女性和27.3％的男性）完成了调查，并被纳入最终分析。最常用的疫苗类型是辉瑞-BioNTech（42.2％），大多数受试者接受了三剂。与男性相比，接受阿斯利康疫苗且不需要在夜间小便的女性比例明显更高（59.1％vs.33.3%；p<0.05)。接受单剂量疫苗的人在夜间排尿五次或更多次的比例高于接受三剂疫苗的人(2.2%vs.0.1%；p<0.05)。
■已发现COVID-19疫苗接种会影响下尿路（LUT）和膀胱过度活动症（OAB）。最初，LUT症状恶化，在45岁以下的个体中，首次接种疫苗后，OABSS-S评分增加。然而,接受第三和第四剂后症状改善。在疫苗接种效果方面观察到性别差异。接种阿斯利康疫苗的男性报告夜间空隙数量较多，而接种了Moderna疫苗的女性报告了更多的白天空隙。
该研究基于一项在线调查，其中包括西班牙语版膀胱过度活动症症状评分（OABSS-S）；2,362名男性和女性回答了该调查。应用排除标准后，1,563名参与者参加了保险。在COVID-19的背景下，个体被问及与其疫苗接种状况和病史相关的几个关键因素。这些因素包括接受的疫苗剂量，所施用的特定类型的疫苗，他们以前是否感染过COVID-19，以及以前感染的频率，如果适用。
■共有1,563名18至45岁的受试者（74.7％的女性和27.3％的男性）完成了调查，并被纳入最终分析。最常用的疫苗类型是辉瑞-BioNTech（42.2％），大多数受试者接受了三剂。与男性相比，接受阿斯利康疫苗且不需要在夜间小便的女性比例明显更高（59.1％vs.33.3%；p<0.05)。接受单剂量疫苗的人在夜间排尿五次或更多次的比例高于接受三剂疫苗的人(2.2%vs.0.1%；p<0.05)。
■已发现COVID-19疫苗接种会影响下尿路（LUT）和膀胱过度活动症（OAB）。最初，LUT症状恶化，在45岁以下的个体中，首次接种疫苗后，OABSS-S评分增加。然而,接受第三和第四剂后症状改善。在疫苗接种效果方面观察到性别差异。接种阿斯利康疫苗的男性报告夜间空隙数量较多，而接种了Moderna疫苗的女性报告了更多的白天空隙。
